- Trade Name: Vyndaqel (FoldRx Pharmaceuticals)
- Indications: Cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults. Transthyretin familial amyloid polyneuropathy (TTR-FAP).
- Class: Transthyretin stabilizer
- Half-life: 49 hours
- FDA Approval Date: 05/03/2019
- Clinically important, potentially hazardous interactions with:
Breast Cancer Resistance Protein inhibitors, Imatinib, Methotrexate, Rosuvastatin - Pregnancy: Based on findings from animal studies, tafamidis may cause fetal harm when administered to a pregnant woman.
Please login to view the rest of this drug profile.
Page last updated 08/20/2025
